Browse the evidence

Obesity drives chronic low-grade inflammation through the expansion of adipose tissue, which shifts the balance of adipokines to favor proinflammatory mediators (like leptin and resistin) and recruit proinflammatory immune cells (M1 macrophages), increasing the risk of metabolic diseases.

Excess body fat, particularly visceral fat, is not just stored energy but an active organ that releases inflammatory signals. This chronic inflammation is a primary driver of type 2 diabetes and cardiovascular disease. Weight loss interventions that reduce adipose tissue mass can help restore the balance of adipokines and reduce this chronic inflammatory state.

Supplemental intakes of EPA and DHA combined up to 5 g/day, and EPA alone up to 1.8 g/day, do not raise safety concerns for adults.

For adults, taking up to 5g/day of combined EPA/DHA or up to 1.8g/day of EPA alone does not raise any safety concerns. There is no official upper limit because these doses are considered safe.

n-3 omega fatty acids reduce inflammation by inhibiting the production of pro-inflammatory eicosanoids (PGE2, TXA2, LTB4) and promoting anti-inflammatory eicosanoids (PGE1, PGI3, LTB5).

Incorporating n-3 omega fatty acids into your diet helps reduce systemic inflammation by shifting your body's production of inflammatory mediators towards anti-inflammatory ones. This is beneficial for conditions like rheumatoid arthritis and inflammatory bowel disease.

Continuous positive airway pressure (CPAP) significantly reduces 24-hour mean arterial blood pressure in patients with moderate-to-severe obstructive sleep apnea, even when cardiovascular risk factors are well-managed with pharmacotherapy.

If you have moderate-to-severe sleep apnea and high blood pressure or heart disease, using CPAP at night can lower your blood pressure, even if you are already taking blood pressure medications. While the drop in blood pressure is modest (about 2-3 mmHg), it is a proven benefit. Supplemental oxygen alone does not provide this blood pressure benefit, so CPAP remains the superior treatment for cardiovascular risk reduction in this population.

Excess visceral fat and upper body subcutaneous fat impair insulin-mediated suppression of free fatty acid (FFA) release, leading to elevated systemic FFA levels that drive hepatic VLDL-triglyceride overproduction and low HDL cholesterol, thereby increasing cardiovascular disease risk.

Focus on reducing visceral fat through lifestyle changes, as this specific fat depot drives harmful metabolic processes like high triglycerides and low HDL. Total weight loss is beneficial, but targeting visceral fat accumulation is key to improving metabolic health and reducing cardiovascular risk.

The association between high BMI and diabetes prevalence is significantly stronger in younger individuals (under 50) compared to older individuals (60+).

If you are under 50, managing your weight is even more critical for preventing diabetes than for older adults. This study found that the link between high BMI and diabetes is much stronger in younger people. Preventing weight gain or losing weight in your 20s, 30s, and 40s offers the greatest protection against developing type 2 diabetes later in life.

Women with PCOS have a significantly higher risk of developing gestational diabetes mellitus (GDM) compared to control women, with PCOS being an independent risk factor.

If you have PCOS and are pregnant or planning to be, you are nearly three times more likely to develop gestational diabetes than women without PCOS. Inform your obstetrician about your PCOS diagnosis early so they can monitor your blood sugar closely during pregnancy.

Insulin resistance (IR) is a major driver of PCOS pathophysiology, present in 65-95% of women with PCOS, and is independent of and exacerbated by obesity.

Insulin resistance is a core feature of PCOS, affecting most women with the condition, regardless of weight. Managing insulin levels is crucial for treating PCOS symptoms and reducing long-term health risks like type 2 diabetes.

The detrimental effects of sleep deprivation on cognitive performance are modulated by circadian phase, being virtually absent during the evening wake maintenance zone and most prominent during early morning hours.

Do not rely on feeling 'fine' in the evening to judge your sleep debt. Your circadian drive masks the effects of sleep loss during the evening. Plan critical tasks for the morning or afternoon, and avoid high-stakes decisions late at night or early morning when circadian and homeostatic pressures align to maximize impairment.

Long-term body weight regulation is achieved through the control of meal size rather than meal frequency or timing, mediated by adiposity signals (leptin and insulin) that modulate sensitivity to meal-ending signals like CCK.

Stop worrying about how many times you eat per day. Your body regulates long-term weight by adjusting how much you eat in each sitting based on your current fat stores. If you are underweight, your body naturally reduces the effectiveness of fullness signals, leading to larger meals. If you are overweight, you naturally eat smaller meals. Focus on consistent food availability and listening to your body's natural satiety cues rather than enforcing arbitrary meal frequencies.

Decreases in circulating leptin during energy restriction contribute to increased hunger and a strong propensity for weight regain.

When you diet, your leptin levels drop, which biologically increases your hunger. This is a normal survival mechanism, not a lack of willpower. Understanding this can help you prepare for increased hunger and plan strategies to manage it, knowing that your body is actively trying to regain weight.

Low leptin levels during fasting stimulate feeding and reduce energy expenditure to conserve energy stores, whereas high leptin levels in the overfed state inhibit food intake and increase energy expenditure.

Your body uses leptin to signal energy status. When you fast, leptin drops, triggering hunger and slowing metabolism to save energy. When you are overfed, leptin rises to curb appetite and burn more energy. In obesity, this system breaks down (leptin resistance), so high leptin levels fail to suppress appetite.

Adiponectin levels are reduced in obesity and are associated with insulin resistance, while higher levels of adiponectin (particularly HMW forms) correlate with improved insulin sensitivity and fatty acid oxidation.

Adiponectin is an 'anti-diabetic' hormone produced by fat cells. Unlike leptin, its levels drop when you are obese. Higher levels, especially the high-molecular-weight form, are linked to better insulin sensitivity and fat burning. Weight loss and exercise can help restore these levels.

Obesity is the primary environmental factor driving insulin resistance and the pathogenesis of Type 2 Diabetes (T2D) through mechanisms involving visceral fat distribution, ectopic lipid deposition, and gut microbiome dysbiosis.

Focus on reducing visceral and ectopic fat through sustainable lifestyle changes, as this is the most effective way to improve insulin sensitivity and prevent Type 2 Diabetes. Prioritize weight management, especially in high-risk groups, as it is the primary driver of the disease.

Low energy availability (EA < 30 kcal/kg FFM/day) in female athletes is associated with reduced blood glucose levels and altered hormone profiles, including lower T3 and elevated cortisol.

Severe energy deficiency can disrupt your hormones and blood sugar. If you are not eating enough to support your training, your body may lower thyroid hormone levels and increase stress hormones like cortisol, which can further impact your health and performance.

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

Vitamin D status influences muscle function through genomic mechanisms involving the Vitamin D Receptor (VDR) and non-genomic rapid calcium handling.

Understanding that Vitamin D acts directly on muscle cells via specific receptors helps explain why deficiency leads to weakness. It is not just about bones.

Metformin reduces the risk of progression from prediabetes to type 2 diabetes by enhancing insulin action in the liver and skeletal muscle, with efficacy approaching that of intensive lifestyle intervention in younger, higher-BMI, or higher-FPG subgroups.

If you have prediabetes, metformin is a proven, safe, and low-cost option to delay or prevent type 2 diabetes. It works best if you are younger, overweight, or have higher fasting glucose. It should be used alongside lifestyle changes, not as a replacement, and requires a prescription.

Activation of the melanocortin-4 receptor (MC4R) by alpha-melanocyte-stimulating hormone (alpha-MSH) decreases energy intake and increases energy expenditure.

Your brain uses a specific hormonal pathway (leptin/insulin -> POMC -> MC4R) to regulate hunger and energy use. When this system works, it helps you stop eating and burn energy. Disruptions in this pathway (due to genetics or obesity) can make this harder, but the mechanism itself is a valid target for understanding appetite control.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes, particularly those with established cardiovascular disease.

If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like liraglutide or semaglutide) are proven to significantly lower your risk of heart attack, stroke, and death. This benefit exists alongside blood sugar control. However, if you have heart failure with reduced ejection fraction, these drugs may increase risks, so discuss your specific heart condition with your doctor before starting.

Semaglutide has a favorable cardiovascular safety profile, with cardiovascular outcome trials (SUSTAIN-6, PIONEER-6) showing no increased risk of major adverse cardiovascular events (MACE) compared to placebo.

Semaglutide is safe for your heart. Large studies have shown it does not increase the risk of heart attack, stroke, or cardiovascular death in people with type 2 diabetes, and may even offer benefits.

Insulin and leptin function as redundant adiposity signals to the brain, where they share downstream melanocortin signaling pathways to regulate food intake and energy expenditure.

Your body uses insulin and leptin to tell your brain how much fat you have stored. When these signals are high, your brain reduces hunger and increases energy use. When they are low (fasting/weight loss), hunger increases. This is a biological defense mechanism, not a failure of willpower.

Insulin acts as a rapid, minute-to-minute indicator of energy balance that tracks acute metabolic changes better than leptin, which reflects stable total fat mass.

Don't expect your body's fat-regulating hormones to react to every single meal instantly. Leptin changes slowly as you gain/lose fat. Insulin reacts quickly to meals but is designed to manage glucose, not just signal fullness. Focus on long-term trends, not daily hormonal spikes.

Ingestion of a mixed meal containing glucose completely suppresses hepatic glucose output within 30 minutes in healthy humans.

When you eat a normal mixed meal, your liver stops releasing glucose into your bloodstream within 30 minutes. This is a normal, healthy physiological response driven by insulin. You do not need to worry about your liver continuing to produce glucose while you are digesting food; your body handles this transition automatically.